A RETROSPECTIVE cohort study has revealed that the use of SGLT2 inhibitors significantly improves kidney health in a diverse group of Asian adults with Type 2 diabetes. The research, conducted by ...

A groundbreaking development in diabetes treatment reveals that SGLT-2 inhibitors significantly reduce dementia risk among type 2 diabetes patients. Recent research demonstrates these medications ...

SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and ...

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher ...

Calorie restriction, physical activity and the drug dapagliflozin caused 44% of participants in a small trial to enter diabetes remission Dapagliflozin is a sodium glucose co-transporter 2 (SGLT2) ...

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much ...

MoA Aggressive Allocation Fund earns a High Process Pillar rating. The most important driver of the rating is its parent firm's impressive long-term risk-adjusted performance, as shown by the firm ...

GLP-1 analogues produce significant weight loss along with an improvement in glycemia. DPP-IV inhibitors are well tolerated, effective and weight neutral. Neither therapy has a proven long-term ...